Related Experiment Video

Updated: Mar 26, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells

Masahiro Zenitani1,2, Takashi Nojiri1, Shuichiro Uehara2

  • 1Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Suita-City, Osaka, Japan.

Cancer Medicine
|January 28, 2016
PubMed

Insights

C-type natriuretic peptide (CNP) combined with sildenafil shows promise for treating rhabdomyosarcoma (RMS). This novel therapy inhibits RMS cell proliferation and tumor growth by targeting the Raf/MEK/ERK pathway with reduced toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Rhabdomyosarcoma (RMS) is a prevalent childhood soft tissue sarcoma with significant treatment-related toxicities.
  • Current therapies for RMS often lead to complications like growth disturbances and secondary cancers, necessitating safer treatment alternatives.
  • C-type natriuretic peptide (CNP) exhibits antiproliferative properties in mesenchymal cells, suggesting potential therapeutic application.

Purpose of the Study:

  • To investigate the efficacy of C-type natriuretic peptide (CNP) in attenuating the proliferation of rhabdomyosarcoma (RMS) cells.
  • To explore the synergistic effects of CNP in combination with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, on RMS growth.

Main Methods:

  • Analysis of guanylyl cyclase B (GC-B) receptor expression in RMS patient samples and cell lines.
  • Establishment of GC-B stable expression RMS cell lines to mimic clinical expression levels.
  • In vitro and in vivo studies assessing the effects of CNP and sildenafil on RMS cell proliferation, signaling pathways (Raf/MEK/ERK), and tumor growth.

Main Results:

  • RMS clinical samples showed higher GC-B expression than cell lines, with expression decreasing in vitro.
  • CNP treatment increased cyclic guanosine monophosphate (cGMP) levels in RMS cells.
  • Combined CNP and sildenafil synergistically inhibited RMS cell proliferation and Raf/MEK/ERK phosphorylation in vitro, and reduced tumor growth in vivo without significant adverse effects.

Conclusions:

  • CNP, in combination with sildenafil, demonstrates significant antiproliferative effects on RMS cells by inhibiting the Raf/MEK/ERK pathway.
  • This combination therapy shows promise as a novel, less toxic therapeutic strategy for rhabdomyosarcoma.
  • Further investigation into CNP and sildenafil as a potential treatment regimen for RMS is warranted.
Keywords:
AntiproliferationCNPERKPDE5 inhibitorcGMP

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.7K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K